focus -WSS

focus

author：focus 2025-09-30 09:29:33 - browse：24

Matts Take Column Illustration — Molly Ferguson for STAT

The news that the weight loss drug Wegovy reduced the risk of heart attacks and strokes in overweight volunteers opens up the door to vastly expanded use of the drug and medicines like it, known as GLP-1 medicines.

That could have a big, positive impact on public health, and it will very likely swell the coffers of the pharmaceutical companies that make these medicines, including Wegovy’s maker, Novo Nordisk, and Eli Lilly, now the most valuable drug company in history thanks largely to hopes for its GLP-1, Mounjaro. These are medicines that could save lives, make money, and perhaps reshape our culture. But they are also, we are learning, not without risk.

So what’s next?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： New documents shed light on MD Anderson Cancer Institute feud

WSS

Medicare Advantage enrollment hits roughly 33.4 million

STAT readers on older presidents, polypills, Medicare, and more

A solution to the after

Surprise medical billing ban raises prices elsewhere

Alabama IVF ruling threatens families facing fatal genetic disease

Obesity drugs seen as possible treatment for liver disease MASH

focus

focus

entertainment

New air purifier tech could be key to improving indoor air quality

A solution to the after

After affirmative action ruling, medical educators look to 'holistic review'

New documents shed light on MD Anderson Cancer Institute feud

United colonoscopy coverage change 'may cost lives,' doctors say

New study raises questions about niacin and heart health

In Memoriam: Notable people who died in 2023

Medicare inequities exacerbate Puerto Rico’s health disparities

Cancer drug shortages should be causing more outrage

NIH study of ME/CFS points to clear biological hallmarks

explore

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Researchers tackle phage therapy hurdles for wider adoption

A new nitrogen execution bill also undermines medical licensing

Medicare Advantage enrollment hits roughly 33.4 million

Abridge raises $150m as clinical notes automation market heats up

entertainment

focus

leisure time

focus